Experienced in Sarcoidosis

Dr. Jeremy Feldman

Pulmonary Medicine
Bend Memorial Clinic LLP
1501 NE Medical Center Dr, 
Bend, OR 
Offers Telehealth
Experienced in Sarcoidosis
Bend Memorial Clinic LLP
1501 NE Medical Center Dr, 
Bend, OR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeremy Feldman is a Pulmonary Medicine provider in Bend, Oregon. Dr. Feldman is rated as an Experienced provider by MediFind in the treatment of Sarcoidosis. His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Pulmonary Fibrosis, Gastrostomy, and Splenectomy.

His clinical research consists of co-authoring 53 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Sarcoidosis.

Specialties
Pulmonary Medicine
Licenses
Critical Care Medicine in AZ
Hospital Affiliations
St Charles Madras
St Charles Medical Center - Bend
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Moda Health
  • EPO
  • PPO
PacificSource
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Prominence Health
  • EPO
  • PPO
Regence
  • EPO
  • PPO
Samaritan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

Bend Memorial Clinic LLP
1501 NE Medical Center Dr, Bend, OR 97701
Other Locations
St. Joseph's Hospital and Medical Center
350 W Thomas Rd, Phoenix, AZ 85013

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety and Tolerability of Liposomal Treprostinil Inhalation Suspension (L606) in Subjects With Pulmonary Arterial Hypertension or Pulmonary Hypertension Associated With Interstitial Lung Disease
A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety and Tolerability of Liposomal Treprostinil Inhalation Suspension (L606) in Subjects With Pulmonary Arterial Hypertension or Pulmonary Hypertension Associated With Interstitial Lung Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2025
Intervention Type: Combination product
Study Drug: L606
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Device, Drug
Study Drug: Treprostinil
Study Phase: Phase 3
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-004)
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-004)
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Biological
Study Drug: Sotatercept
Study Phase: Phase 3
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Completed
Publish Date: June 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension
A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drug: Rodatristat Ethyl
Study Phase: Phase 2
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Biological
Study Drug: Sotatercept
Study Phase: Phase 3
IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients With Pulmonary Arterial Hypertension (PAH)
IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients With Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2024
Intervention Type: Drug
Study Drug: AV-101
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
Enrollment Status: Terminated
Publish Date: July 27, 2023
Intervention Type: Combination product
Study Drug: INOpulse
Study Phase: Phase 3
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Completed
Publish Date: April 19, 2023
Intervention Type: Drug, Other
Study Drug: Sotatercept
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 13 Less Clinical Trials

53 Total Publications

Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR).
Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR).
Journal: American journal of respiratory and critical care medicine
Published: March 04, 2025
Similar Doctors
Experienced in Sarcoidosis
Dr. Louis D'avignon
Pulmonary Medicine
Experienced in Sarcoidosis
Dr. Louis D'avignon
Pulmonary Medicine

Bend Memorial Clinic LLP

1501 NE Medical Center Dr, 
Bend, OR 
 (0.1 miles away)
541-382-2811
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Louis D'avignon is a Pulmonary Medicine provider in Bend, Oregon. Dr. D'avignon is rated as a Distinguished provider by MediFind in the treatment of Sarcoidosis. His top areas of expertise are Hospital-Acquired Pneumonia, Atypical Pneumonia, Eosinophilic Asthma, Gastrostomy, and Endoscopy.

Experienced in Sarcoidosis
Dr. Kevin Sherer
Pulmonary Medicine
Experienced in Sarcoidosis
Dr. Kevin Sherer
Pulmonary Medicine

Bend Memorial Clinic LLP

1501 NE Medical Center Dr, 
Bend, OR 
 (0.1 miles away)
541-382-2811
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kevin Sherer is a Pulmonary Medicine provider in Bend, Oregon. Dr. Sherer is rated as a Distinguished provider by MediFind in the treatment of Sarcoidosis. His top areas of expertise are Lung Metastases, Pulmonary Fibrosis, Central Sleep Apnea, and Obstructive Sleep Apnea.

Experienced in Sarcoidosis
Dr. Jonathan Brewer
Pulmonary Medicine
Experienced in Sarcoidosis
Dr. Jonathan Brewer
Pulmonary Medicine

Bend Memorial Clinic LLP

1501 NE Medical Center Dr, 
Bend, OR 
 (0.1 miles away)
541-382-2811
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jonathan Brewer is a Pulmonary Medicine provider in Bend, Oregon. Dr. Brewer is rated as an Advanced provider by MediFind in the treatment of Sarcoidosis. His top areas of expertise are Obstructive Sleep Apnea, Central Sleep Apnea, Bronchitis, Endoscopy, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Feldman's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 34 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile